Subtopic Deep Dive
Hormonal Contraceptive Safety
Research Guide
What is Hormonal Contraceptive Safety?
Hormonal Contraceptive Safety evaluates risks of venous thromboembolism, cardiovascular events, and breast cancer associated with combined oral contraceptives and progestin-only methods through cohort studies and meta-analyses.
Researchers assess formulations differing in oestrogen dose and progestogen type, such as desogestrel, drospirenone, and levonorgestrel. Key studies include Danish cohort analyses by Lidegaard et al. (2009, 698 citations) and MEGA case-control by van Hylckama Vlieg et al. (2009, 651 citations). Over 10 major papers since 1998 report relative risks from 0.9 to 2-fold elevations.
Why It Matters
Risk profiles from Lidegaard et al. (2011, BMJ, 588 citations) guide CDC eligibility criteria (Curtis et al., 2016, 1442 citations), informing prescriptions for 100 million users worldwide. Elevated VTE risks with desogestrel or drospirenone versus levonorgestrel (Lidegaard et al., 2009) prompt regulatory label changes in Europe. Breast cancer associations (Mørch et al., 2017, 597 citations) versus null findings (Marchbanks et al., 2002, 534 citations) shape shared decision-making in primary care.
Key Research Challenges
Confounding in Observational Data
Cohort studies like Lidegaard et al. (2009) adjust for age and BMI, but residual smoking and genetic factors bias VTE risk estimates. Meta-analyses struggle with heterogeneous progestogen definitions. Over 700 citations highlight inconsistent adjustments across Danish and MEGA studies.
Rare Event Risk Estimation
Thrombotic stroke risks below 1/10,000 users challenge power in trials (Lidegaard et al., 2012, 578 citations). Case-control designs like van Hylckama Vlieg et al. (2009) rely on hospital controls prone to selection bias. Absolute risks remain low despite 1.5-2-fold relative increases.
Long-term Cancer Risk Attribution
Breast cancer odds ratios vary: 1.24 current use (Mørch et al., 2017) contrasts neutral findings in Marchbanks et al. (2002). Duration-response patterns complicate causality versus screening effects. Conflicting results across 500+ citation papers impede consensus guidelines.
Essential Papers
Contraceptive failure in the United States
James Trussell · 2011 · Contraception · 1.6K citations
U.S. Medical Eligibility Criteria for Contraceptive Use, 2016
Kathryn M. Curtis, Naomi K. Tepper, Tara C. Jatlaoui et al. · 2016 · MMWR Recommendations and Reports · 1.4K citations
The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics...
U.S. Selected Practice Recommendations for Contraceptive Use, 2016
Kathryn M. Curtis, Tara C. Jatlaoui, Naomi K. Tepper et al. · 2016 · MMWR Recommendations and Reports · 755 citations
The 2016 U.S. Selected Practice Recommendations for Contraceptive Use (U.S. SPR) addresses a select group of common, yet sometimes controversial or complex, issues regarding initiation and use of s...
Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contraception
Regulation, Task Force on Postovulatory Methods of Fertility · 1998 · The Lancet · 731 citations
Hormonal contraception and risk of venous thromboembolism: national follow-up study
Øjvind Lidegaard, Ellen Løkkegaard, A. L. Svendsen et al. · 2009 · BMJ · 698 citations
Objective To assess the risk of venous thrombosis in current users of different types of hormonal contraception, focusing on regimen, oestrogen dose, type of progestogen, and route of administratio...
The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study
Astrid van Hylckama Vlieg, Frans M. Helmerhorst, Jan P. Vandenbroucke et al. · 2009 · BMJ · 651 citations
Currently available oral contraceptives still have a major impact on thrombosis occurrence and many women do not use the safest brands with regard to risk of venous thrombosis.
Contemporary Hormonal Contraception and the Risk of Breast Cancer
Lina Steinrud Mørch, Charlotte Wessel Skovlund, Philip C Hannaford et al. · 2017 · New England Journal of Medicine · 597 citations
The risk of breast cancer was higher among women who currently or recently used contemporary hormonal contraceptives than among women who had never used hormonal contraceptives, and this risk incre...
Reading Guide
Foundational Papers
Start with Lidegaard et al. (2009, 698 citations) for VTE baseline by progestogen; van Hylckama Vlieg MEGA (2009, 651 citations) confirms oestrogen/progestogen effects; Trussell (2011, 1566 citations) contextualizes efficacy-safety balance.
Recent Advances
Mørch et al. (2017, NEJM, 597 citations) on contemporary breast cancer risks; Lidegaard et al. (2012, NEJM, 578 citations) for stroke/MI dose-responses; Curtis CDC updates (2016, 1442/755 citations) integrate findings.
Core Methods
Danish registry cohorts track users for incident VTE; MEGA case-control recruits thrombosis cases/controls; CDC panels grade evidence (1-4 scale) for eligibility by condition.
How PapersFlow Helps You Research Hormonal Contraceptive Safety
Discover & Search
Research Agent uses searchPapers and citationGraph on 'Lidegaard venous thromboembolism' to map 698-citation 2009 BMJ paper to 5 related Danish cohorts. exaSearch uncovers progestogen-specific risks; findSimilarPapers links Mørch 2017 (597 citations) to Marchbanks 2002 null findings.
Analyze & Verify
Analysis Agent applies readPaperContent to extract VTE odds ratios from Lidegaard et al. (2011), then verifyResponse with CoVe chain-of-verification flags contradictions versus Curtis CDC criteria. runPythonAnalysis computes meta-analytic risk ratios using GRADE for moderate evidence on drospirenone (20% VTE elevation).
Synthesize & Write
Synthesis Agent detects gaps in cardiovascular data post-2012 via Lidegaard papers; Writing Agent uses latexEditText for risk tables, latexSyncCitations for 10-paper bibliography, and latexCompile for guideline drafts. exportMermaid visualizes progestogen VTE risk hierarchies.
Use Cases
"Meta-analyze VTE risks by progestogen type from Danish cohorts"
Research Agent → searchPapers + citationGraph → Analysis Agent → readPaperContent (Lidegaard 2009/2011) → runPythonAnalysis (pandas meta-regression on ORs) → CSV of pooled RR=1.7 for desogestrel.
"Draft LaTeX table comparing CDC MEC ratings for hormonal methods"
Research Agent → exaSearch 'Curtis 2016 MEC' → Synthesis Agent → gap detection → Writing Agent → latexEditText + latexSyncCitations (1442-cite Curtis) + latexCompile → PDF guideline table.
"Find analysis code for contraceptive failure rates"
Research Agent → paperExtractUrls (Trussell 2011) → paperFindGithubRepo → githubRepoInspect → runPythonAnalysis (NumPy Pearl Index calculator) → validated failure rates by method.
Automated Workflows
Deep Research workflow synthesizes 50+ papers into GRADE-graded systematic review of VTE risks, chaining searchPapers → readPaperContent → runPythonAnalysis for forest plots. DeepScan 7-step analyzes Lidegaard cohorts with CoVe checkpoints on oestrogen dose effects. Theorizer generates hypotheses on progestogen mechanisms from Mørch/Marchbanks contradictions.
Frequently Asked Questions
What defines Hormonal Contraceptive Safety?
It assesses VTE, stroke, MI, and breast cancer risks by formulation via cohorts/meta-analyses, focusing on oestrogen dose and progestogen type like levonorgestrel versus drospirenone.
What methods dominate research?
National cohorts (Lidegaard et al., 2009 Denmark, 698 citations) and case-controls (van Hylckama Vlieg MEGA, 651 citations) quantify relative risks adjusted for confounders.
What are key papers?
Top: Curtis CDC MEC (2016, 1442 citations), Lidegaard VTE (2009, 698), Mørch breast cancer (2017, 597), Trussell failure (2011, 1566).
What open problems persist?
Reconciling breast cancer conflicts (Mørch 1.24 OR vs Marchbanks neutral), genetic modifiers of VTE, and long-term progestin-only cardiovascular data lack large RCTs.
Research Reproductive Health and Contraception with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Hormonal Contraceptive Safety with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers